Online citations, reference lists, and bibliographies.
← Back to Search

The Biological Activity Of Auranofin: Implications For Novel Treatment Of Diseases

J. Madeira, D. Gibson, W. Kean, A. Klegeris
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
More than 30 years ago, auranofin was developed for the treatment of rheumatoid arthritis as a substitution for the injectable gold compounds aurothiomalate and aurothioglucose. Both the ease of oral administration over intramuscular injections and more potent anti-inflammatory effects in vitro made auranofin seem like an excellent substitute for the traditional injectable gold compounds. Despite efficacy in the treatment of both rheumatoid arthritis and psoriasis, currently, auranofin is seldom used as a treatment for patients with rheumatoid arthritis as more novel anti-rheumatic medications have become available. Despite the decline in its clinical applications, research on auranofin has continued as it shows promise in the treatment of several different diseases. In recent years, advances in technology have allowed researchers to use molecular techniques to identify novel mechanisms of action of auranofin. Additionally, researchers are discovering potential new applications of auranofin. Dual inhibition of inflammatory pathways and thiol redox enzymes by auranofin makes it a new candidate for cancer therapy and treating microbial infections. This review will summarize recently obtained data on the mechanisms of action of auranofin, and potential new applications of auranofin in the treatment of various diseases, including several types of leukaemia, carcinomas, and parasitic, bacterial, and viral infections.
This paper references
10.32388/rx9at4
Auranofin.
W. Kean (2020)
10.1016/0002-9343(83)90481-3
Biologic actions and pharmacokinetic studies of auranofin.
D. T. Walz (1983)
10.1126/SCIENCE.6429854
Intestinal uptake and metabolism of auranofin, a new oral gold-based antiarthritis drug.
K. Tepperman (1984)
10.1016/0049-0172(85)90037-X
The history of gold therapy in rheumatoid disease.
W. Kean (1985)
10.1128/iai.56.4.726-728.1988
Quantitative relationship of Treponema denticola to severity of periodontal disease
L. Simonson (1988)
10.1016/S0950-3579(05)80005-6
The gold complexes.
G. Champion (1990)
10.1016/S0950-3579(05)80019-6
Intramuscular versus oral gold therapy.
W. Kean (1990)
10.1016/0738-081X(91)90083-W
Systemic gold therapy.
K. Papp (1991)
10.1038/384529A0
Host factors and the pathogenesis of HIV-induced disease
A. Fauci (1996)
10.1177/135245859600100611
A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis
BW vanOosten (1996)
Treatment of HIV associated psoriatic arthritis with oral gold.
D. Shapiro (1996)
10.1016/0014-5793(96)00065-8
Inactivation of tissue inhibitor of metalloproteinase‐1 by peroxynitrite
E. Frears (1996)
Disease-modifying drugs series editor : T. PULLAR AURANOFIN
W. Kean (1997)
10.1073/PNAS.94.26.14848
Targeted gene deletion of heme oxygenase 2 reveals neural role for carbon monoxide.
R. Zakhary (1997)
10.1006/BBRC.1997.6618
Thioredoxin reductase activity is decreased by selenium deficiency.
K. Hill (1997)
10.1172/JCI119268
Antiinflammatory potential of lipoxygenase-derived eicosanoids: a molecular switch at 5 and 15 positions?
C. Serhan (1997)
10.1093/RHEUMATOLOGY/36.8.870
Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis.
A. Glennås (1997)
10.1016/S0014-2999(97)00118-0
Dual effects of auranofin on prostaglandin E2 production by rat peritoneal macrophages.
M. Yamashita (1997)
10.3109/10715769809065797
The oxidative inactivation of tissue inhibitor of metalloproteinase-1 (TIMP-1) by hypochlorous acid (HOCI) is suppressed by anti-rheumatic drugs.
F. Shabani (1998)
Life in the 21st century - a vision for all.
Jones Js (1998)
10.1016/s0031-9406(05)61461-7
Life in the 21st century - a vision for all.
J. Jones (1998)
10.1016/S0014-2999(99)00707-4
Auranofin inhibits interleukin-1beta-induced transcript of cyclooxygenase-2 on cultured human synoviocytes.
R. Yamada (1999)
10.1146/ANNUREV.MED.50.1.291
Immunologic therapy of multiple sclerosis.
B. Arnason (1999)
10.1172/JCI4165
Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency.
A. Yachie (1999)
10.4049/jimmunol.164.11.5981
Thiol-Reactive Metal Compounds Inhibit NF-κB Activation by Blocking IκB Kinase1
K. Jeon (2000)
10.1007/s002800000166
Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes
M. McKeage (2000)
10.1016/S0169-4758(00)01750-6
Malaria research in the post-genomic era.
D. Carucci (2000)
Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.
A. Griffioen (2000)
Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase.
K. Jeon (2000)
10.1186/bcr315
Hypoxia and oxidative stress in breast cancer: Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer
N. Brown (2001)
10.1172/JCI11914
Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer.
Y. Yamamoto (2001)
10.1016/S0140-6736(00)04046-0
Inflammation and cancer: back to Virchow?
F. Balkwill (2001)
Inflammation and cancer: back to Virchow? Lancet 357:539–545
F Balkwill (2001)
10.1016/S1471-4906(03)00181-9
Heme oxygenase-1: unleashing the protective properties of heme.
L. Otterbein (2003)
10.1007/s00280-003-0726-5
Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity
Elizabeth O. Hileman (2004)
10.1111/J.0022-202X.2004.23487.X
Heat shock-induced matrix metalloproteinase (MMP)-1 and MMP-3 are mediated through ERK and JNK activation and via an autocrine interleukin-6 loop.
Chi-hyun Park (2004)
10.1016/J.CANLET.2003.08.029
The IKK/NF-κB activation pathway—a target for prevention and treatment of cancer
F. Greten (2004)
10.1038/sj.bjp.0705708
Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro
I. S. Kim (2004)
The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer.
F. Greten (2004)
10.1007/BF00302664
Inhibition of neovascularization in vivo by gold compounds
R. Saura (2004)
10.1016/J.TIV.2004.11.001
Anti-rheumatic gold compounds as sublethal modulators of monocytic LPS-induced cytokine secretion.
I. Stern (2005)
10.1038/sj.bjp.0706360
The role of p38 MAPK activation in auranofin‐induced apoptosis of human promyelocytic leukaemia HL‐60 cells
S. Park (2005)
10.1073/PNAS.0511319103
Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway.
C. Korherr (2006)
10.1158/0008-5472.CAN-05-3948
TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer.
M. Kelly (2006)
10.1016/J.PT.2006.02.015
Giardia and Cryptosporidium join the 'Neglected Diseases Initiative'.
(2006)
10.1016/J.CBI.2005.12.009
Free radicals, metals and antioxidants in oxidative stress-induced cancer.
M. Valko (2006)
10.1016/J.BBRC.2006.09.097
Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4.
H. Youn (2006)
10.1016/J.TIV.2005.11.001
Gold-induced reactive oxygen species (ROS) do not mediate suppression of monocytic mitochondrial or secretory function.
Y. Omata (2006)
10.1038/448645A
New uses for old drugs
C. Chong (2007)
10.1371/JOURNAL.PMED.0040206
Thioredoxin Glutathione Reductase from Schistosoma mansoni: An Essential Parasite Enzyme and a Key Drug Target
Angela N Kuntz (2007)
10.1007/s10787-007-0021-x
Clinical pharmacology of gold
W. Kean (2008)
10.1016/J.FREERADBIOMED.2006.12.021
Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells.
C. Marzano (2007)
10.1111/j.1365-2567.2007.02679.x
Auranofin blocks interleukin‐6 signalling by inhibiting phosphorylation of JAK1 and STAT3
Nam‐Hoon Kim (2007)
10.1002/cbdv.200890140
The Influence of Auranofin, a Clinically Established Antiarthritic Gold Drug, on Bone Metabolism: Analysis of Its Effects on Human Multipotent Adipose‐Derived Stem Cells, Taken as a Model
C. Chiellini (2008)
10.1016/j.bcp.2008.08.021
The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation.
A. G. Cox (2008)
10.1038/bjp.2008.161
Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia
S. Talbot (2008)
10.1074/jbc.M710609200
Platyhelminth Mitochondrial and Cytosolic Redox Homeostasis Is Controlled by a Single Thioredoxin Glutathione Reductase and Dependent on Selenium and Glutathione*
Mariana Bonilla (2008)
10.1016/j.febslet.2008.02.028
New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications
A. Sannella (2008)
10.1007/S12272-008-1122-9
Auranofin inhibits overproduction of pro-inflammatory cytokines, cyclooxygenase expression and PGE2 production in macrophages
Shinha Han (2008)
10.1371/journal.ppat.1000456
The Heart Is an Early Target of Anthrax Lethal Toxin in Mice: A Protective Role for Neuronal Nitric Oxide Synthase (nNOS)
M. Moayeri (2009)
10.1215/15228517-2009-025
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.
K. Ichimura (2009)
10.1007/s00775-009-0466-z
Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au–Se adduct
S. Jackson-Rosario (2009)
10.1074/jbc.M109.003756
Free Thiol Group of MD-2 as the Target for Inhibition of the Lipopolysaccharide-induced Cell Activation*
Mateja Manček-Keber (2009)
10.1038/nm.1972
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
N. Chomont (2009)
10.1128/JB.00164-09
Inhibition of Selenium Metabolism in the Oral Pathogen Treponema denticola
S. Jackson-Rosario (2009)
10.1074/jbc.M109.020701
Inhibition of Schistosoma mansoni Thioredoxin-glutathione Reductase by Auranofin
F. Angelucci (2009)
10.1007/s10534-010-9293-5
HIV therapeutic possibilities of gold compounds
P. Fonteh (2010)
10.1254/JPHS.09330FP
Auranofin, a gold(I)-containing antirheumatic compound, activates Keap1/Nrf2 signaling via Rac1/iNOS signal and mitogen-activated protein kinase activation.
Nam‐Hoon Kim (2010)
10.1128/AAC.00772-10
Auranofin Protects against Anthrax Lethal Toxin-Induced Activation of the Nlrp1b Inflammasome
Zachary L. Newman (2010)
10.1016/j.febslet.2010.02.042
Mitochondrial respiratory chain involvement in peroxiredoxin 3 oxidation by phenethyl isothiocyanate and auranofin
K. Brown (2010)
10.1007/s00436-010-1867-1
In vitro killing action of auranofin on Taenia crassiceps metacestode (cysticerci) and inactivation of thioredoxin–glutathione reductase (TGR)
J. Martínez-González (2010)
10.1007/s12272-010-0618-2
TBK1-targeted suppression of TRIF-dependent signaling pathway of toll-like receptor 3 by auranofin
Se-jeong Park (2010)
10.1358/dot.2010.46.12.1586465
A report from the XVIII International AIDS Conference. (July 18-23, 2010-Vienna, Austria).
X. Rabasseda (2010)
10.2131/JTS.36.635
Auranofin protects against cocaine-induced hepatic injury through induction of heme oxygenase-1.
T. Ashino (2011)
10.1016/j.leukres.2010.05.011
The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-κB activity.
A. Nakaya (2011)
10.1074/jbc.M111.284612
Thioredoxin Reductase-2 Is Essential for Keeping Low Levels of H2O2 Emission from Isolated Heart Mitochondria*
Brian A. Stanley (2011)
10.1039/c1mt00062d
Gold compounds as therapeutic agents for human diseases.
S. Berners-Price (2011)
10.1097/QAD.0b013e328347bd77
Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension
M. Lewis (2011)
10.1016/j.bbrc.2011.12.009
Investigation of a potential mechanism for the inhibition of SmTGR by Auranofin and its implications for Plasmodium falciparum inhibition.
Antonia Caroli (2012)
10.1097/MOG.0b013e32834bc9a9
Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options
A. Lo Vecchio (2012)
10.1038/nm.2758
A high throughput drug screen for Entamoeba histolytica identifies a new lead and target
A. Debnath (2012)
Novel clinical applications of auranofin 305



This paper is referenced by
10.3390/molecules26123772
Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization
Ayman Abo Elmaaty (2021)
10.1039/d1dt02488d
Medicinal Au(I) compounds targeting urease as prospective antimicrobial agents: unveiling the structural basis for enzyme inhibition.
L. Mazzei (2021)
10.1007/s11686-021-00337-z
Repurposing auranofin for treatment of Experimental Cerebral Toxoplasmosis.
I. F. Abou-El-Naga (2021)
10.33609/2708-129X.87.02.2021.95-106
SYNTHESIS AND PROPERTIES OF NEW NANOSYSTEMS OF ARGENTUM
О. Berezhnytska (2021)
10.1007/978-3-030-87016-4_30
Multilayered Modelling of the Metallation of Biological Targets
Iogann Tolbatov (2021)
10.1021/acs.jmedchem.0c01926
Gold(I) Phosphine Derivatives with Improved Selectivity as Topically Active Drug Leads to Overcome 5-Nitroheterocyclic Drug Resistance in Trichomonas vaginalis.
Y. Miyamoto (2021)
10.1016/j.redox.2021.101949
Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer
Laurie Freire Boullosa (2021)
10.3390/biomedicines9050504
Strategies for the Improvement of Metal-Based Chemotherapeutic Treatments
D. Cirri (2021)
10.1016/j.ijantimicag.2021.106425
Antimicrobial effect of auranofin against Acanthamoeba spp.
Alvie Loufouma Mbouaka (2021)
10.1093/noajnl/vdab075
A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3
M. Halatsch (2021)
10.3389/fimmu.2021.683694
Will Auranofin Become a Golden New Treatment Against COVID-19?
K. Sonzogni-Desautels (2021)
10.3390/nano11030808
Synthesis of Gold Nanoparticles by Using Green Machinery: Characterization and In Vitro Toxicity
Ahmed Al Saqr (2021)
10.3389/fphar.2021.739481
Gold Compounds and the Anticancer Immune Response
Ling Zhou (2021)
10.1093/bib/bbaa265
Drug-drug similarity measure and its applications.
Lan Huang (2020)
10.1016/B978-0-444-64225-7.00001-8
An overview of the role of metals in biology
R. Crichton (2020)
10.1016/j.jinorgbio.2020.111079
Structure-activity relationships in a series of auranofin analogues showing remarkable antiproliferative properties.
I. Landini (2020)
10.1016/j.brainres.2020.147022
Subchronic administration of auranofin reduced amyloid-β plaque pathology in a transgenic APPNL-G-F/NL-G-F mouse model
Jolanta Upīte (2020)
10.1101/2020.05.28.120642
Molecules inhibit the enzyme activity of 3-chymotrypsin-like cysteine protease of SARS-CoV-2 virus: the experimental and theory studies
Zhesheng He (2020)
10.1016/j.lfs.2020.117635
Synthesis, characterization and anticancer activity in vitro evaluation of novel dicyanoaurate (I)-based complexes.
A. Karadağ (2020)
10.1016/j.jinorgbio.2020.111023
Anti-fibrotic activity of gold and platinum complexes - Au(I) compounds as a new class of anti-fibrotic agents.
M. Stratton (2020)
10.3390/molecules25215075
Repurposing Auranofin and Evaluation of a New Gold(I) Compound for the Search of Treatment of Human and Cattle Parasitic Diseases: From Protozoa to Helminth Infections
L. Feng (2020)
10.3389/fchem.2020.00543
Recent Advances of Gold Compounds in Anticancer Immunity
Shuang Yue (2020)
10.4062/biomolther.2020.122
Auranofin Enhances Sulforaphane-Mediated Apoptosis in Hepatocellular Carcinoma Hep3B Cells through Inactivation of the PI3K/Akt Signaling Pathway
Hyun Hwangbo (2020)
10.1016/bs.adioch.2019.10.008
Metal N-heterocyclic carbene complexes in medicinal chemistry
I. Ott (2020)
10.3390/cancers11060780
Gold as a Possible Alternative to Platinum-Based Chemotherapy for Colon Cancer Treatment
Inés Mármol (2019)
10.1080/00958972.2019.1583333
Pharmacological properties of dicyanidoaurate(I)-based complexes: characterization and single crystal X-ray analysis
A. Karadağ (2019)
10.1158/1078-0432.CCR-18-2751
Auranofin Protects Intestine against Radiation Injury by Modulating p53/p21 Pathway and Radiosensitizes Human Colon Tumor
D. Nag (2019)
10.1016/j.sopen.2019.05.004
Antineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models
Mayrim V. Rios Perez (2019)
10.1021/ACSMEDCHEMLETT.8B00585
Inhibition Mechanism of Urease by Au(III) Compounds Unveiled by X-ray Diffraction Analysis.
L. Mazzei (2019)
10.1016/j.jinorgbio.2019.110807
Assembly behavior of amylin fragment hIAPP19-37 regulated by Au(III) complexes.
Xiangyi Huang (2019)
10.1016/j.biochi.2019.03.015
Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug.
Xiaonan Zhang (2019)
10.1016/J.TRECHM.2019.05.001
Extrapolating the Fragment-Based Approach to Inorganic Drug Discovery
Lucinda K. Batchelor (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar